DEBORAH HORVITZ: Open Payments
NPI 1427457142 · WARWICK, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,125 in 120 payments from 14 companies in 2025. Trend: 2023 $2,048 · 2024 $2,331 · 2025 $2,125
Food & beverage: $2,125
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $443 |
| Vanda Pharmaceuticals Inc. | 14 | $325 |
| Otsuka America Pharmaceutical, Inc. | 17 | $289 |
| Axsome Therapeutics, Inc. | 8 | $208 |
| Alkermes, Inc. | 9 | $200 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $167 |
| Lundbeck LLC | 17 | $153 |
| E.R. Squibb & Sons, L.L.C. | 6 | $110 |
| Teva Pharmaceuticals USA, Inc. | 3 | $63 |
| Sage Therapeutics, LLC | 3 | $61 |
Products named: VRAYLAR, REXULTI, FANAPT, Auvelity, CAPLYTA, LYBALVI, COBENFY, ARISTADA.
Industry payments across RI — which companies pay providers there.
